Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
mc67.... Thanks
for posting that link ( https://www.facebook.com/BouleyBotanical )
I was able to open it and did not see anything NRTI related mentioned. I did however see something for a March 5 2015 gathering. I think their page needs to be updated.
Thanks for providing the link. Not a member and did not know I could view a page. Not able to respond unless I join.
A PR tomorrow morning before the opening
would be nice.
Hope we see something showcasing details of the Launch.
Anybody see anything today from NRTI on their Facebook page or on the Chef David Bouley Facebook page. I am not a member so cant access.
I hope the share price decline is not related to any delays!
We need a nice NRTI PR!
Good luck to us all.
CN .. Here's an NRTI job for you
From the website.. they will consider remote work to promote NRTI products on the internet...
Careers
Social Media Intern
Position Summary
This role is about speaking in our brand voice for either Surgex Sports Nutrition or Bikini Ready. We are seeking people to communicate for these brands online on our blogs, on Facebook, on Twitter, on Pinterest, or elsewhere, as required. For Surgex, interest in sports is key, particularly pro football, college football, and fantasy football. General interest in sports, fitness, and nutritional supplements is also important. For Bikini Ready, interest in women’s pro surfing is helpful. General interest in sports, fitness, diet, and fashion are also useful.
The roles are part-time, 20 hours per week.
We will consider remote work for these roles, although we would like to meet you at our headquarters in Newark, New Jersey.
If you are well-spoken, smart, enthusiastic, entrepreneurial, and a problem solver, apply now.
Responsibilities
Proven social media skills
Excellent communicator
High energy and enthusiasm
Should have experience working with teams
Time-conscious, deadline-conscious
Experience working, managing a weekly and monthly promotional calendar
Some experience in social media platforms like Sprout is preferred
Interested candidates please email Stacey Eng at seng@inergetics.com
Martha Stewart opens cafe...
Martha Stewart just opened up a coffee/tea cafe serving pastries too in the MSL Omnimedia's corporate headquarters. Maybe down the road they can offer protein shakes and smoothies as offered in Muscle Maker Grills! What a way to cross sell!!
Se the PR from Mar 12, 2015
NEW YORK, March 12, 2015 /PRNewswire/ -- Martha Stewart Living Omnimedia (NYSE: MSO) today announces the opening of its first Martha Stewart Cafe, located in the historic Starrett-Lehigh building, home to Martha Stewart Living Omnimedia's corporate headquarters. The cafe will offer handcrafted espresso beverages and teas. The menu, personally curated by Martha Stewart, uses only the finest sourced beverages and ingredients.
Martha Stewart Cafe
"I am thrilled to open the Martha Stewart Cafe. It's a place inspired by my world travels where anyone can come and enjoy a smooth, well-balanced, beautifully handcrafted cappuccino, latte, macchiato, or just plain Americano. In addition, you must try our artisanal teas – they are the finest available anywhere," said Martha Stewart, MSLO Founder and Chief Creative Officer.
The Martha Stewart Cafe draws its menu inspiration from the artisanal cafes of Europe. Along with hot beverages, it will serve cold-brew iced coffee. The cafe is proud to partner with Kobrick Coffee, a New York City-based and family-owned roaster that sourced the beans for the custom "Martha's Blend" coffee served at the cafe, as well as Martha's favorite espresso bean, which is roasted in small batches in Trieste, Italy.
Artisanal loose-leaf teas, provided by Wei Bertram of Connecticut-based Arogya Tea, are also available. These include Martha's Breakfast Blend, a signature blend of Assam long leaf and Chinese black teas; Da Hong Pao, a legendary Oolong hand-rolled and roasted in China; a nutty, subtly sweet Buckwheat tea; and more.
Featured pastries will also be served at the Cafe, and have been hand-selected by Martha from her favorite bakeries, restaurants, and chefs. ChikaLicious, Baked, Bien Cuit, Balthazar, and more will provide selections that will vary daily.
Espresso and coffee beverages range in price from $1.50 – $4. Pastries range in price from $2 – $5. "Martha's Blend" beans are available by the bag for $13.50 – $15. Loose-leaf tea is available by the canister for $20.
The Martha Stewart Cafe is located at 601 W. 26th Street in Manhattan and is open Monday through Friday from 7 a.m. to 4 p.m. For more information and to join the conversation, visit MarthaStewartCafe.com.
Roth conference today.....
Yes ....
Sorry, forgot about that. You are right.
CC next week March 16, 2015
Apricus Biosciences Announces Corporate Update and Fourth Quarter and Year-End 2014 Financial Results Conference Call
Apricus Biosciences, (MM) (NASDAQ:APRI)
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and year-end 2014 financial results will be released on Monday, March 16, 2015. Company management will host a conference call on Monday, March 16, 2015, at 8:30 a.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial 855-780-7196 (Domestic) or 631-485-4867 (International). The conference ID number is 3374804. The live audio webcast can be accessed via the Investors section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 90 days following the live call.
Info about Hy-Vee
From their web page
Company commitment to healthy lifestyles
Over $8 billion in sales annually...
Hy-Vee operates more than 230 retail stores in eight Midwestern states, including Illinois, Iowa, Kansas, Minnesota, Missouri, Nebraska, South Dakota and Wisconsin.
Mission Statement
Making lives easier, healthier, happier.
The Hy-Vee Story
In 1930, Charles Hyde and David Vredenburg opened a small general store in Beaconsfield, Iowa. That store grew to become Hy-Vee – a company known for excellent service and reasonable prices. As an employee-owned company, Hy-Vee encourages each of its more than 70,000 employees to help guide the company. Its eight decades of outstanding success is a testament to those employees’ hard work and dedication to the vision of its founders. Today, Hy-Vee is synonymous with quality, variety, value and superior customer service. Its slogan, "A Helpful Smile in Every Aisle," expresses the foundation of the company’s operating philosophy.
Hy-Vee is a touchstone for its customers’ desire for information on diet, nutrition and wellness topics. The company’s commitment to healthy lifestyles is evidenced by ever-growing HealthMarket departments featuring natural and organic products, the consulting services of in-store dietitians and chefs, the NuVal Nutritional Scoring System, and consumer and employee wellness programs. The company also sponsors the annual Hy-Vee Triathlon for professional and amateur athletes, the Hy-Vee Road Races during Drake Relays weekend, and a series of kids’ triathlons and road races for youngsters every summer.
With sales of more than $8 billion annually, Hy-Vee ranks among the top 25 supermarket chains and the top 50 private companies in the United States. Its 235 stores are located in eight Midwestern states: Iowa, Illinois, Missouri, Kansas, Nebraska, South Dakota, Minnesota and Wisconsin. Distribution centers are in Chariton, Iowa, and Cherokee, Iowa, with a third perishable operation in Ankeny, Iowa. Hy-Vee’s corporate office is located in West Des Moines, Iowa. Its campus includes a 12,000-square-foot conference center for meetings, training and continuing education programs.
NEWS...
Inergetics to Attend Hy-Vee Company-Wide General Merchandise Show on March 11, 2015
9:00a ET March 10, 2015 (PR NewsWire) Print
Inergetics, Inc. (OTCBB: NRTI), a world-class developer of nutritional and consumer health products, today announced that the company will attend the Hy-Vee General Merchandise Show on March 11, 2015 in Iowa.
"Inergetics is pleased and excited to attend this major event which allows us to showcase our complete line of Martha Stewart(TM) Essentials vitamins/supplements to Hy-Vee's team members. It's important to note that Hy-Vee was one of the first major retailers to carry our Martha Stewart Essentials line when we launched last year which speaks volumes about their commitment to innovative new products," said Jim Kras, CMO of Inergetics. "We value our partnership with Hy-Vee, as they are a very progressive grocer that recognizes the unique quality, safety and value our leading NSF(R) Certified, whole-food based Martha Stewart Essentials line provides to their discerning female customers."
The Hy-Vee Company-Wide General Merchandise Show/Meeting will be held at the Iowa Events Center on March 11th, 2015. Information about Inergetics and its family of health and wellness products will be available at booth W306.
For more information, please contact Inergetics at 908-604-2500.
Inergetics Media ContactKARV CommunicationsJonathan Leibowitz(212) 333-0273Inergetics@KARVCommunications.com
About Inergetics, Inc.Inergetics' portfolio of brands includes: Martha Stewart(TM) Essentials, a complete line of NSF(R) Certified, whole-food-based supplements created specifically for women; Surgex(R) Sports Nutrition, the preferred nutritional supplement of Army Sports; Bikini Ready(R), a leader in active lifestyle solutions; SlimTrim, the affordable, premium value diet brand; and OmEssentials(R), a line of scientifically advanced nutritional supplements designed to further the health and wellness of yoga practitioners and active individuals. Inergetics' brands are available domestically and internationally at over 20,000 premier locations including Akins, Bed Bath & Beyond, Bi-Lo, Cardinal Health, Drug Emporium, Fruth Pharmacy, H-E-B, Harmon, Harris Teeter, Harveys, Ingles, Meijer, Navarro Pharmacies, Price Chopper, PriceSmart, ShopRite/Wakefern, Walgreens, Whole Foods and Winn-Dixie as well as leading e-tailers such as Amazon, Bodybuilding.com, Bulu Box, CVS.com, Drugstore.com, iHerb, LuckyVitamin.com, Swanson, Vitacost, and Zulily.
To learn more about Inergetics, visit www.inergetics.com, and the Inergetics brands' websites at: www.marthastewartessentials.com, www.surgexsports.com, www.surgexsportsblitz.com, www.slimtrim1.com, www.slimtrim.net, www.bikinireadylifestyle.com, www.kahunasands.com, www.omessentials.com.
Only one reason an insider buys
To make money!
Interview with Dwight Babcock 2/17/15
http://wallstreetanalyzer.com/isoray-inc-nyseisr-ceo-dwight-babcock/
INTERVIEW TRANSCRIPTS:
WSA: Good day from Wall Street. This is Juan Costello, Senior Analyst with the Wall Street Analyzer. Joining us today is Dwight Babcock, the CEO of IsoRay Inc. The company trades on the New York Stock Exchange, ticker symbol ISR. Thanks for joining us today Dwight.
Dwight Babcock: Juan, thank you very much for inviting me.
WSA: Certainly, now starting off please give us a history and overview there of the company for some of our listeners that are new to your story.
Dwight Babcock: Sure. Juan, as you know, in the past when we have spoken that IsoRay was originally formulated by a group of highly recognized scientists and medical specialists for the use of using Cesium-131 to fight prostate cancer. That was its initial directive and that is what we have pursued since that original foundation of IsoRay. The interesting thing is that Cesium, which many of your listeners may not know and readers is that Cesium was really the choice of the Federal Government for prostate cancer for seed brachytherapy many, many years ago, but did not have the ability to bring it in at a cost-effective price. That has been resolved with IsoRay and in its patented techniques can now bring medical grade Cesium-131 in seed form and in liquid form to treat cancers, not only of the prostate, but now we have advanced into far more aggressive cancers such as brain, head and neck, lung, and GYN cancers. So we’ve come a long way in the last seven or eight years.
WSA: Yeah certainly and so yeah, in terms of Cesium, can you talk about the recent positive results there from UPMC.
WSA: Certainly, and I think for the readers to understand best what we have is we have an FDA approval that our isotope is allowed to be placed in any solid tumor throughout the body. It is a very large wide open market for us, and as I said early on, the destiny of IsoRay was geared to the prostate arena. Seeds were currently being used, they still are in seed brachytherapy, it is still probably the most successful means of treating prostate cancer if you are at a lower or immediate risk and can be used in combination with any other form of procedure. If people talk about chemotherapy, if people talk about external radiation, and ultimately even if you want to have a prostatectomy, the seeds would not inhibit that process if there was a failure.
Cesium recently announced it had just completed a 10-year study, which is required time for this particular body site being prostate. Obviously, prostate is considered a very slow growing cancer and it took a number of years to grow a proper database of patients who had been treated. While we have already treated over 8000 patients now to date, the initial population had to then go through a 5-year period because the first measurement point was biochemical control, PSA bounce at a 5-year mark. I am happy to say that we rank the highest of any of the prostate brachytherapy seeds at this point in time in control of the cancer as well as any other modalities that we do in fact compete with, such as external beam and prostatectomy. So it has been a fabulous result that we got from that last peer-reviewed report.
That followed on the heels of two other very outstanding reports where we are taking the company after more aggressive cancers that are killing people at a much faster rate and have no great cure and solution and that would be brain cancers and that would be three forms of brain cancer, true brain cancer, which is glioblastoma, that would be metastatic brain cancers coming from some other source to the brain, and meningioma, a tumor-based cancer. That paper was released by Cornell recently on metastatic cancer showing at the time 100% of local control as well as no necrosis and damaging other brain cells within the cavity that had been resected–phenomenal results.
And again, GYN is another paper that was released on a patient base and it was released after only a year-and-a-half of time because these women all who had recurring cancers were in a dire straits to have significant surgical procedures that would have left them really between one and two bags required to go through the balance of their life and our seeds I am happy to say were used in a trial there and all patients have avoided that surgery to date and with fabulous results.
WSA: Yeah certainly, and so what are some of the other key trends that you are focusing on right now in this sector. I guess we could primarily talk about the prostate cancer study there in Russia and how you position the company to capitalize.
Dwight Babcock: Well again, we have FDA approval for our products and we have a CE mark for all our products throughout the world. So what we are allowed to do in Russia, they were announcing a grand opening of a brand new mega center that was being geared totally to cancer treatment, at least a new wing that they had built, it’s state-of-the-art and they wanted to introduce Cesium because they think that is one of the few new products that is available in the marketplace that is showing that it can compete with the current standard of care, and you remember Juan, we are dealing with people who have failed standard of care, sometimes as many as four times before they try Cesium and this is just a typical process that the medical industry goes through where they don’t easily adopt, they are not fast to move, but they use them on their critical patients, who have failed other treatments. So we are very proud to have been chosen by the Russian Federation to join them in Russian and have several procedures performed before some 100 plus physicians watching around the country.
WSA: Certainly, and anything else Dwight that you feel makes IsoRay unique from some of the others players there in the sector?
Dwight Babcock: Well, I would say there is another press release that was out that is an anatomical type of answer, but what we really were able to do for a young lady in Peru, if you read this one, you saw that we for the first time really attacked cancer that was inoperable, but we were able to place our seeds within the tumor. We normally excavate the tumor and place our seeds or our balloon catheter, which we fill with liquid inside the cavity created by the excavation of the tumor, but in this case.
WSA: Right, for brain cancer, right?
Dwight Babcock: Yes, yes. There was a little glioma right on the top of the brainstem. This young lady was in a very sad state, not able to walk and stay awake, sit up and I can tell you after three weeks she was home walking on her own. She is back at school now at six months. The cancer has been reduced down by 70% and shows that there has been no re-growth and no fluid buildup, so we think we have a dead cancer body that is in there and we are very optimistic about how well this has gone. These are not always curative in any way, shape, or form, but they are certainly opportunities that people out there need to know do exist and we are having absolutely fabulous success.
WSA: Well good. And what are some of the key goals or milestones that you are hoping accomplish here over the next 6 to 12 months?
Dwight Babcock: Well, what we are really looking to do is we are going to expand our prostate effort to now bring with the papers that we are starting to get released. We will bring those forward to the traditional users of seeds in the marketplace who may have been waiting for peer-reviewed papers before they run the risk of modifying their own personal practice. So we will be reaching out faster and with more definitive information on our product that we can stand behind in the prostate arena.
The brain results, I think that is going to become IsoRay’s Holy Grail, I mean we are finding a home there where we are doing marvelous things. If you look back at the Barrow Neurological Center Report and their results on all three forms of brain cancer, they are having fabulous results and they have a technique and a process, which we are supporting and want to move ahead with, so we think that is going to be an outstanding market for us going forward. And as well as now that we have good data being accumulated on lung, we have a paper out on GYN, although GYN is not going to be a huge market, we do see that as something that we really can be a standout in.
Part of the reason that we are so successful in killing some of these aggressive cancers compared to any other isotope that is available in the low-dose range is that our half-life is 9.7 days. So that says we give half our dose during that period of time and about at 30 days, we have given some 90% of the entire dose that we intended to give to that cancer site. This is in the range of six times faster than that of iodine and it makes a lot of sense even to a layperson that if brain cancer is doubling every 30 days, how can you attempt to win the battle if you don’t deliver even half your dose in 60 days. So you are losing ground. Cesium is the clear choice for its half life and energy qualities.
WSA: Right and perhaps you can talk to us a little bit of your background and experience there and the key management behind the scenes.
Dwight Babcock: Well, I think you know I have to always refer to myself as kind of the generalist. I run an insurance company. I have had a computer firm that automated insurance companies all around the world. I think I am in that generalist category and I think that is probably what IsoRay needed when I came from the Board down to be a CEO, but I am surrounded by world-recognized scientists and medical physicists, a tremendous staff that has never had a ride up by the FDA for any infraction or anything out of the ordinary occurring, the quality assurance systems that we have in place are absolutely fabulous.
So it is not really an individual, it’s just a great, great team that we have there in Richland, Washington. We have people schooled in medicine and they know the benefits of brachytherapy and the benefits you can bring to humanity and they are really driven to that end.
WSA: Well, good, and so as far as investors and the financial committee are concerned as the company last year was one of the top, actually the fifth highest percentage gainer in the New York Stock Exchange group, do you believe that investors are finally starting to realize the potential and your upside and what are some of the other things that you wish they better understood about the company?
Dwight Babcock: Well, I’d say there are two things. I think when we talk about the upside of the company, I think it has a tremendous upside and I think we are looking to do a lot of good things in the next 12-24 months, but I think first we are the only one that has Cesium-131 available. It is proving its efficacy in the marketplace. The market is beginning to recognize it. I think the things that I would tell you that the market doesn’t understand from time to time in my estimation is that when we announce a new body sector we are entering, that means a key opinion leader or a thought leader at a major medical institution probably is trying to do something positive for a patient that is so critically ill and is failing all other treatments.
That we hope leads to a study, which means we accumulate data on a number of patients with common problems and then we ultimately get a paper that qualifies with its integrity and we are never involved in the data collection or we are not involved in the data calculations. It is all institutional based. So we hope that those get peer-reviewed, we hope to get critical review, and we can then go out to the general market and expand the marketplace. I feel like I make a comment about a new body site or a new technique, even the stereotactic with this young lady in Peru and if someone thinks next month everyone is going to jump on board, when that’s not the case. The other thing I would tell you is that I think people don’t understand as well is that we are listed as a medical device being that we are seed-based product, meaning our radioisotope is placed into a titanium seed and it qualifies under the medical device field.
We are blessed in that we are able to sell our product into all our efficacy studies. We are very much like a pharma though. We have to prove the efficacy and compare ourselves to standard of care that exists today in all modalities, and in doing that, you know, IsoRay has had a relatively flat line, which says two things. One, we have been continuing to sell into our studies, which is a benefit to the shareholders because we don’t have to raise money and just give away the product like a pharmaceutical does, but if someone looks at it not recognizing that also some of the studies that have ended in their required data accumulation are still buying from us because those in house understand the results that their patients are having, but they are not yet able to broadcast it.
So I think people look at revenue. I often kid that we’d almost be a better off and compared much closer to a pharmaceutical if we had no revenue, but I do think we have avoided raising another $40,000,000 to $50,000,000 to this point by virtue that we have been able to sell our product to the market.
WSA: Certainly well, that is a very key point and so once again joining us today is Dwight Babcock, the CEO and Chairman of IsoRay Inc. trading on the New York Stock Exchange, ticker symbol ISR, trading $1.32 a share, market cap is $72 Million, and before we conclude here Dwight to recap some of your key points, why do you believe investors should consider your company as a good investment opportunity today?
Dwight Babcock: Well, I think we are a company that’s geared to ultimately be returning somewhere in the 50% gross margin range. I think our, well I don’t know that we will ever be in the near term what I would call that hockey stick look of growth. I think we are going to be slow and steady because each of the institutions and/or users will find one, two, or three cases a month coming on board that fit the criteria of the selection, until such time as we are accepted as a standard of care at which time the world will change for IsoRay.
Rather than just being kind of a newly build of slow growth, we are going to have a far more rapid growth when people are given a choice to have a procedure that is done at the time of surgery if they are going to have the tumor removed, we are placed at that time in the quality of life of them being able to return home and not return back to the hospital for 20 or 30 treatments or whatever the follow-on modality requires, ours says you are one-and-done and you can be with family, friends, and recuperate and never have to worry about coming back.
WSA: Well, we certainly look forward to continue to track the company’s growth and report on your upcoming progress and we would like to thank you for taking the time to join us today Dwight and update our investor audience on IsoRay. It is always good to have you on.
Dwight Babcock: Thank you Juan. I really appreciate the time.
Alliqua BioMedical, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results
Date : 02/24/2015 @ 7:30AM
Source : GlobeNewswire Inc.
Stock : Alliqua Biomedical, Inc. (MM) (ALQA)
Quote : 5.94 -0.03 (-0.50%) @ 10:00AM
Today : Tuesday 24 February 2015
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
Q4 Highlights:
Total revenue increased 255% year-over-year to approximately $1.7 million. Organic revenue growth was 128% year-over-year.
Proprietary products revenue increased 1,170% year-over-year to approximately $1.3 million. Organic product revenue growth was 609% year-over-year.
On November 3rd, the Company announced Alliqua's Biovance® Human Amniotic Membrane Allograft has been assigned a new and unique, Level II Healthcare Common Procedure Coding System (HCPCS) product reimbursement Q code (Q4154) by the Centers for Medicare and Medicaid Services ("CMS"). This decision was a significant step towards obtaining comprehensive coverage reimbursement coverage for Biovance in the outpatient setting.
Highlights Subsequent to Quarter-End:
On January 5th, the Company announced a Group Purchasing Agreement with Premier, Inc.
On February 2nd, the Company announced a definitive agreement to acquire Celleration, Inc. for an initial purchase price of approximately $30.4 million, which is comprised of both cash and stock.
"Our fourth quarter operating and financial performance represents a strong end to fiscal year 2014 – an important year for Alliqua BioMedical," said David Johnson, Chief Executive Officer of Alliqua. "The profile of the Company changed dramatically in 2014, with growth in all areas of our organization – from leadership, to sales force and distribution infrastructure, to our portfolio of proprietary advanced wound care products - Alliqua BioMedical made significant progress towards our strategic objective of becoming a market-leading advanced wound care solutions provider."
"We expect continued progress in fiscal year 2015 and look forward to the continued growth in sales of our proprietary products – including our amniotic tissue membrane product Biovance – and the anticipated contributions in the second half of the year from our acquisition of Celleration which we announced earlier this month. We are pleased with our Company's notable progress in just a brief period of time, and we remain focused on continuing to execute our plan which we expect to drive revenue growth and market share gains, improving financial performance and above-average shareholder returns in 2015 and beyond."
Alliqua BioMedical, Inc. and Subsidiaries
Revenue Summary
($, Thousands) Three Months Ended December 31, Fiscal Year Ended December 31
2014 2013 2014 2013
Proprietary Products $1,349.0 $106.2 $3,003.5 $179.0
Contract Manufacturing 315.3 362.6 1,782.6 1,618.7
Revenue, net $1,664.3 $468.8 $4,786.1 $1,797.7
Fourth Quarter 2014 Results:
Total revenue for the fourth quarter of 2014 increased $1.2 million, or 255% year-over-year, to $1.7 million. Sales of the Company's proprietary products – including hydrogels, Sorbion, Biovance and Therabond – increased $1.2 million, or 1,170%, year-over-year. Fourth quarter 2014 revenue includes contributions from Choice Therapeutics, which we acquired in May 2014, of approximately $596 thousand. Excluding the contributions from the acquisition of Choice Therapeutics, the Company's proprietary products revenue increased in the fourth quarter 609%, year-over-year
Gross profit for the fourth quarter of 2014 increased $0.9 million year-over-year to $0.8 million, or 46.7% of sales. The increase in gross margin was driven by the change in product mix due to increased sales of proprietary products which represented 81% of sales in the fourth quarter of fiscal year 2014 compared to 23% of sales during the fourth quarter last year. Gross margin on proprietary product sales was 73% in the fourth quarter of 2014.
Total operating expenses for the fourth quarter of 2014 decreased approximately $7.2 million, or 54% year-over-year, to $6.1 million. Fourth quarter of 2013 total operating expenses included an impairment charge of $8.1 million related to in-process research and development for the Company's Hepamate technology. Excluding the impairment charge, adjusted operating expenses increased $0.9 million, or 18%, year-over-year. The increase in adjusted operating expenses in the fourth quarter of 2014 was driven primarily by higher compensation and benefits related to increased headcount compared to the prior year and the incremental expenses related to our acquisition of Choice Therapeutics. Stock-based compensation was $1.7 million and $2.6 million for the three months ended December 31, 2014 and 2013, respectively.
Loss from operations for the fourth quarter of 2014 was $5.3 million compared to a loss of $13.4 million last year. Net loss for the fourth quarter of 2014 was $5.4 million, compared to a net loss of $14.9 million for the same period last year.
Fiscal Year 2014 Results:
Total revenue for the twelve months ended December 31, 2014 increased $3.0 million, or 166% year-over-year, to $4.8 million. Sales of the Company's proprietary products – including hydrogels, Sorbion, Biovance and Therabond – increased $2.8 million, or 1,577%, year-over-year. Fiscal year 2014 revenue includes contributions from the acquisition of Choice Therapeutics in May 2014 of approximately $1.5 million. Excluding the contributions from the acquisition of Choice Therapeutics, the Company's proprietary products revenue increased 742%, year-over-year.
Gross profit for fiscal year 2014 increased $1.8 million to $1.5 million, or 31.7% of total sales, compared to a gross loss of $249 thousand last year. The increase in gross margin was due to a higher concentration of proprietary product sales. Product sales had a gross margin of 70% in fiscal year 2014. Net loss for the fiscal year of 2014 was $25.4 million compared to a net loss of $22.0 million for the same period last year.
As of December 31, 2014, the Company had $16.8 million in cash and cash equivalents, compared to $12.1 million at December 31, 2013. The increase was largely attributable to net financing proceeds of $14.4 million, proceeds from the exercise of stock options and warrants totaling $6.6 million offset by cash used in operating activities of $13.3 million and $2.0 million used for the purchase of Choice Therapeutics during the twelve months ended December 31, 2014.
Updated Fiscal Year 2015 Revenue Outlook
The Company is updating its revenue guidance for the fiscal year 2015 period. The updated guidance reflects the expected incremental contributions from the acquisition of Celleration, based on a closing date of June 30th.
For the fiscal-year ending December 31, 2015, the Company expects total revenue of $15.5 million to $18 million, representing growth at the mid-point of the range of approximately 250% year-over-year. This compares to the Company's previous expectation for total revenue in fiscal year 2015 in the range of $11 million to $13 million. Celleration revenue for the second-half of fiscal year 2015 is expected in the range of $4.5 million to $5.0 million. We expect sales from our contract manufacturing business to reflect slightly positive growth year-over-year, therefore, the growth rates reflected in the Company's revenue guidance for fiscal year 2015 are primarily generated by expected growth in the sale of the Company's proprietary products.
Conference Call
The Company will host a teleconference at 8:00 a.m. Eastern Time on February 24th to discuss the results of the quarter and fiscal year, and to host a question and answer session. Those interested in participating on the call may dial 888-576-4387 (719-457-2689 for international callers) and provide access code 6093126 approximately 10 minutes prior to the start time. A live webcast of the call will be made available on the investor relations section of the Company's website at http://ir.alliqua.com.
For those unable to participate, a replay of the call will be available for two weeks at 888-203-1112 (719-457-0820 for international callers); access code 6093126. The webcast will be archived on the investor relations section of Alliqua's website.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond® 3D advanced dressing which incorporates the TheraBond® 3D Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company's liquidity to pursue its complete business objectives; inadequate capital; the Company's ability to obtain reimbursement from fourth party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company's products; technical problems with the Company's research and products; the Company's ability to expand its business through strategic acquisitions; the Company's ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our most recent Annual Report on Form 10-K filed with the SEC, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
ALLIQUA BIOMEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
December 31, December 31,
2014 2013
ASSETS:
Current Assets:
Cash and cash equivalents $16,770,879 $12,100,544
Accounts receivable 968,616 156,831
Inventory, net 1,411,748 501,469
Prepaid expenses and other current assets 477,824 88,390
Total current assets 19,629,067 12,847,234
Improvements and equipment, net 1,434,027 1,745,248
Intangible assets, net 4,387,293 2,258,477
Goodwill 4,100,295 425,969
Other assets 173,042 174,640
Total assets $29,723,724 $17,451,568
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable $1,757,742 $746,609
Accrued expenses and other current liabilities 2,067,859 1,340,057
Payable for distribution rights -- 333,333
Warrant liability 304,223 933,465
Total current liabilities 4,129,824 3,353,464
Contingent consideration 2,931,598 --
Deferred tax obligation 67,000 53,000
Other long-term liabilities 84,071 92,408
Total liabilities 7,212,493 3,498,872
Commitments and Contingencies
Stockholders' Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding -- --
Common Stock, par value $0.001 per share, 45,714,286 shares authorized; 16,202,689 and 11,484,191 shares issued and outstanding as of December 31, 2014 and 2013, respectively 16,203 11,484
Additional paid-in capital 92,537,742 58,538,491
Accumulated deficit (70,042,714) (44,597,279)
Total stockholders' equity 22,511,231 13,952,696
Total liabilities and stockholders' equity $29,723,724 $17,451,568
ALLIQUA BIOMEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended December 31, Year Ended December 31,
2014 2013 2014 2013
Revenue, net of returns, allowances and discounts $1,664,268 $468,834 $4,786,131 $1,797,745
Cost of revenues 886,730 539,964 3,270,955 2,047,033
Gross profit (loss) 777,538 (71,130) 1,515,176 (249,288)
Operating expenses
Selling, general and administrative (1) 6,071,993 5,187,844 26,155,008 11,719,998
Research and product development -- -- -- 63,204
Impairment of in-process research and development -- 8,100,000 -- 8,100,000
Acquisition-related expenses -- -- 546,970 --
Change in fair value of contingent consideration liability 37,564 -- 231,598 --
Total operating expenses 6,109,557 13,287,844 26,933,576 19,883,202
Loss from operations (5,332,019) (13,358,974) (25,418,400) (20,132,490)
Other income (expense)
Interest expense -- (1,759) (384) (4,807)
Interest income 7,984 2,838 30,739 2,913
Change in value of warrant liability (24,066) (1,589,763) (43,390) (1,833,498)
Total other expense (16,082) (1,588,684) (13,035) (1,835,392)
Loss before income tax provision (5,348,101) (14,947,658) (25,431,435) (21,967,882)
Income tax provision 3,500 -- 14,000 9,000
Net loss (5,351,601) (14,947,658) (25,445,435) (21,976,882)
Deemed dividend to preferred stockholders -- (462,006) -- (462,006)
Net loss attributable to common stockholders $(5,351,601) $(15,409,664) $(25,445,435) $(22,438,888)
Basic and diluted net loss per common share $(0.34) $(1.68) $(1.74) $(3.14)
Weighted average shares used in computing basic and diluted net loss per common share 15,767,165 9,182,948 14,628,981 7,140,613
(1) Inclusive of stock-based compensation of $1,655,185 and $2,615,728 for the three months ended December 31, 2014 and 2013, respectively, and $10,530,265 and $5,513,861 for the years ended December 31, 2014 and 2013, respectively.
CONTACT: Investor Relations:
Westwicke Partners on behalf of Alliqua BioMedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
Alliqua BioMedical, Inc. to Present at Upcoming Investor Conferences
LANGHORNE, Pa., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced that company management will participate in the following investor conferences:
The 2015 RBC Capital Markets' Global Healthcare Conference in New York, New York
David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will present on Wednesday, February 25th at 8:30 a.m. Eastern Time (ET).
The 35th Annual Cowen Health Care Conference in Boston, Massachusetts
David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will participate in a fireside chat on Tuesday, March 3rd at 9:20 a.m. Eastern Time (ET).
Live webcasts of the conference presentation and the fireside chat will be available on the investor relations section of the Company's website at http://ir.alliqua.com. Archives of the conference webcasts will be available for replay following the events.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond® 3D advanced dressing which incorporates the TheraBond® 3D Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
CONTACT: Investor Relations:
Westwicke Partners on behalf of Alliqua Biomedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
TRTC issues 2015 guidance. No mention of NRTI
TRTC mentions their own cannabis producing company, IVXX but not NRTI.
Terra Tech Gives Update on Nevada Medical Cannabis and National Initiatives
Terra Tech Corp. 20 hours ago GlobeNewswire
Irvine, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Terra Tech Corp (TRTC), is pleased to update shareholders on Nevada Medical Cannabis efforts as well as additional efforts throughout the country. The company recently announced that MediFarm, MediFarm I, and MediFarm II, have all received provisional certificates from the State of Nevada in each local jurisdiction where they applied for a Medical Marijuana Establishment license. Collectively, these subsidiaries were issued a total of four Dispensary provisional certificates, two Cultivation provisional certificates and two Production provisional certificates spanning both Northern and Southern Nevada. Below is a summary of current status in each region:
City of Las Vegas Dispensary- MediFarm received a provisional operational certificate from the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health on 11/3/2014. Subsequently MediFarm has submitted our Las Vegas Business License Application to the City of Las Vegas Department of Planning Business Licensing Division on 11/12/2014. MediFarm is finalizing our design so that we may submit our construction documents for permitting and once approved, will begin construction. After completing construction and obtaining all required approvals and certifications from the local and state agencies, MediFarm will commence operations. The company anticipates the retail facility to be open and able to service patients by summer 2015.
Clark County Dispensaries, Cultivation and Production- MediFarm received four provisional operational certificates for two dispensaries, a cultivation and a production facility from the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health on 11/3/2014. Medifarm received approval from the Clark County Department of Comprehensive Planning-Land Use on 6/25/2014 for its cultivation and production facilities.
MediFarm has not received final approval from the Clark County Department of Comprehensive Planning-Land Use for its two dispensaries. On 12/29/2014, the Clark County Commission voted 5 to 1 to formally deny, without prejudice, all applications for Special Use Permits (SUPs) that had previously been held in abeyance, including the 2 applications submitted by MediFarm for medical marijuana dispensaries in Clark County, Nevada. This denial was not directed at any particular applicant, but came as a recommendation from Clark County's District Attorney to the Commissioners in an effort to reconcile the state and local selection processes. The state had issued 18 provisional certificates for dispensaries in Clark County, including 2 to MediFarm, but only 10 of these had received Clark County SUPs.
The action by the Commissioners followed a Clark County District Court order issued on 12/26/2014 in the lawsuit filed by five dispensary applicants who received approval from Clark County, but not the state. Those applicants had asked the court to rule that the state improperly approved applicants who lacked county zoning approval. However, District Judge Kathleen Delaney found the state appropriately followed the law in choosing which applications to approve and had substantially complied with Nevada's Medical Marijuana Law in NRS Chapter 453A. Judge Delaney further stated "The Legislature clearly did not intend for the local jurisdictions ... to have de facto authority to dictate to the Division whom it may consider for registration."
The plaintiffs in the lawsuit filed an amended complaint on 12/29/2014 and Clark County has asked to intervene in the litigation.
Medifarm has sued Clark County, Nevada for Declaratory and Injunctive Relief, and for Judicial Review pursuant to NRS 278.3195, of Clark County's decision to deny Medifarm's application for a Special Use Permit ("SUP") that would permit Medifarm to operate a medical marijuana dispensary in unincorporated Clark County. Specifically, Medifarm has alleged that Clark County, during the SUP approval process in June 2014, preselected SUP applicants that Clark County wanted as dispensary operators by issuing SUPs pursuant to Title 30 of the Clark County Code before the applications were even due to be submitted to the State of Nevada for dispensary registration certificates. Clark County deselected Medifarm by holding Medifarm's SUP application in abeyance, even though Clark County staff indicated that Medifarm met all of the requirements necessary for the issuance of a SUP.
While its SUP application was held in abeyance by Clark County, Medifarm applied for and received a dispensary registration certificate from the State. Several of the applicants that had been preselected by Clark County did not. Clark County, unhappy with the State's issuance of certificates to dispensary applicants different than those preferred by Clark County, then denied Medifarm's application for a SUP without explanation. This was a clear attempt by Clark County to inappropriately control the approval process for dispensaries, even though the State was primarily tasked with assessing and ranking applicants for such dispensaries. In so doing, Clark County acted in an arbitrary and capricious manner, and violated both Clark County Code as well as Nevada law. Medifarm's lawsuit seeks Judicial Review of Clark County's actions, and an affirmative injunction requiring Clark County to consider and approve Medifarm's SUP application.
The company wants to make certain an appropriate judicial review of the process is conducted. The only manner to facilitate a judicial review is by formally filing a lawsuit. Regardless of the outcome, the company plans to respect the results of this process and is focused on building out their six other facilities throughout the state.
MediFarm is finalizing the design of our cultivation and production facilities in Clark County so that we may submit our construction documents for permitting. Once approved, the company will commence construction. After completing construction and obtaining all required approvals and certifications from the local and state agencies, MediFarm will commence operations. The Company anticipates these production and cultivation facilities to be online by Q4, 2015.
Washoe County Cultivation and Production- MediFarm I received a provisional operational certificate from the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health on 11/3/2014. MediFarm II has submitted its business license application to the Washoe County Business License Divisionfor their review and approval. After completing construction and obtaining all required approvals and certifications from the local and state agencies, MediFarm II will commence operations. The Company anticipates the production and cultivation facilities to be online by Q4, 2015.
Reno Dispensary- MediFarm I received a provisional operational certificate from the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health on 11/3/2014. MediFarm I has submitted its business license application to the City of Reno Business License Division for their review and approval. MediFarm Iis finalizing the design of our dispensaryso that we may submit our construction documents for permitting, once approved we will commence construction. After completing construction and obtaining all required approvals and certifications from the local and state agencies, MediFarm I will commence operations. The company anticipates the retail facility to be open and able to service patients by summer 2015.
"We are working diligently with our architects to finalize our final construction-ready plans. We are building what we believe are world-class facilities in what will likely be one of the largest markets in the country. While our goal is to be one of the first to market, we are taking our time to do it right. We think Nevada is going to be a sizable market and one that may grow significantly if recreational use successfully passes in 2016. We are building for our future there and not rushing the process," explains Derek Peterson, CEO of Terra Tech. "We have broad coverage throughout the state, even with the two retail locations in Clark County on hold. Our city of Las Vegas location is in close proximity to The Las Vegas Strip and is also easily accessible to local residents. The dispensary location in Reno is situated on a main road in a developing part of town. Our objective is to have our retail facilities open by this coming summer and our cultivation and production facilities in operation within the fourth quarter of 2015. We are actively sourcing premier medication to offer patients for the handful of months before we are cultivating our own. We are using the same guidelines and standards we use to source our premium product for our IVXX brand."
Florida- Terra Tech is keeping a close eye on Florida's developing opportunities. The manner in which the law is being implemented has been challenged, reviewed and is currently changing. Once the process is clarified the company will make a decision whether or not they are competing now or waiting for a broader law to pass in the future.
New York- The Company is actively pursuing the New York market. They have retained the law firm Malkin & Ross to lobby on their behalf throughout New York. MediFarm is currently developing a strategic advisory board and operational team in an effort to effectively compete for a chance to operate medical cannabis facilities in the state.
Edible Garden- The Edible Garden(R) brand is continuing to add retailers throughout the country. The company has recently finished the installation of their Dutch hydroponic moveable tables. This is the first application of the newest Dutch farming technology within the US. This has allowed the company to reduce labor costs and increase margins on its products. EG has recently introduced a new product called the Living Salad, which is a mixture of various living lettuces grown together in one pot. After a successful test the company is ramping up production and increasing the number of retail outlets carrying this item. In addition the company has expanded their supermarket penetration throughout the Midwest by adding new Kroger retailers every month.
IVXX- The Company recently announced a new brand of exceptional quality cannabis products called IVXX, which is a wholly owned subsidiary of Terra Tech. The company made its first sales of IVXX in December 2014 and is planning a full launch in early March 2015. The company is also launching a full website in the next few weeks in support of the brand, IVXX.com. Through the website, patients and brand enthusiasts will be able to learn more about the products offered by IVXX, find local retailers, as well as purchase IVXX branded gear. The Oakland-based lab will be producing all of the concentrates for IVXX.
The Company will issue additional updates to investors in the near future.
About Terra Tech
Terra Tech Corp. (TRTC) through its wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies. The company integrates best-of-breed hydroponic equipment with proprietary software and hardware to provide sustainable solutions for indoor agriculture enterprises and home practitioners. Our complete product line is available at specialty retailers throughout the United States, and via our website. Through its wholly-owned subsidiary Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as Shoprite, Food Emporium and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, and Pennsylvania. MediFarm LLC is focused on medical cannabis businesses throughout Nevada.
For more information about Terra Tech Corp visit: www.terratechcorp.com
ALQA
Alliqua Biomedical: An Attractive Opportunity In The Wound Care Space
Feb. 9, 2015 11:19 AM ET About: Alliqua, Inc. (ALQA) From SA
Disclosure: The author is long ALQA. (More...)
Summary
Alliqua Biomedical this week announced the acquisition of privately held Celleration.
Alliqua’s offer values Celleration at 3.5x sales, which is in-line with the valuation of other privately held companies acquired in recent years.
Listed companies in the wound care space though trade at 10x sales.
Alliqua’s multiple based on FY2015 sales estimate is just 4x.
As Alliqua grows in size through accretive acquisitions like Celleration, its multiple will move in-line with the average.
Alliqua Biomedical (NASDAQ:ALQA) is a Langhorne, Pennsylvania-based company providing advanced wound care solutions. This week, ALQA was in the news after announcing that it will acquire Celleration Inc., a Minnesota-based privately held medical device company providing advanced wound care products.
The acquisition is part of ALQA's strategy to boost its top line. At the same time, the company is looking to take advantage of the opportunity that is currently on offer in the wound care space, which includes public and private companies.
So what is the opportunity here? Acquisitions in the wound care space in recent years have shown that privately held companies can fetch between 2-4x sales. However, listed companies like MiMedx (NASDAQ:MDXG) and Osiris Therapeutics Inc. (NASDAQ:OSIR) are valued at around 10x sales. ALQA itself is valued at 27x sales. However, the company's sales this year will be significantly boosted by the acquisition of Celleration. Based on the FY2015 sales estimate of roughly $30 million and 20 million shares outstanding, ALQA is valued at just 4x sales, which is well below the average for other players in the wound care treatment market. By continuing to acquire privately held wound care companies at a multiple of between 2x and 4x sales, ALQA could significantly boost its revenue. And as the company grows in size, its multiple should also move in-line with those of its bigger rivals. This means that the stock could generate significant returns in the medium term.
Recent Transactions that highlight the discount
In the last few years, the $21 billion wound care market has seen a number of acquisitions. The interesting thing about these acquisitions is that they have involved a public and a private company.
In December 2010, MDXG acquired Surgical Biologics for $7.25 million. In FY2010, Surgical Biologics had $2.2 million in sales, which means that MDXG's offer valued Surgical Biologics at 3.3x sales. Interestingly, MDXG expected the acquisition to accrete over $7 million to the top line in 2011.
In 2012, Derma Sciences (NASDAQ:DSCI) acquired MedEfficiency for $14.5 million. DSCI's offer valued MedEfficiency at 2.7x sales.
Last year in May, Alliqua itself acquired Choice Therapeutics for $4 million in a cash and stock deal. The transaction valued Choice Therapeutics at 2.2x sales. The latest acquisition from ALQA this week continues the trend seen in the wound care market in terms of valuation. ALQA has offered to acquire Celleration for an initial purchase price of approximately $30.4 million in cash and stock. Celleration's sales during the fiscal year ended December 31, 2014, were approximately $8.7 million, which translates to a valuation of roughly 3.5x sales.
Brief on the regenerative wound care market
The Wound Care products market has three major divisions: Traditional (sutures, bandages, tape, etc.), Advanced (antimicrobial, alginate, foam, hydrogel, hydrocolloid dressings) and Regenerative (bioengineered skin, skin substitutes). The total wound care market is worth about $21 billion in 2015, and is projected to grow to $67.5 billion in 2020. "Four major companies, including Smith & Nephew (NYSE:SNN), Kinetic Concepts (KC), Molnlycke, and ConvaTec comprise more than 55% of the $5 billion advanced wound care market, according to Justin Smith, analyst at Societe Generale," which is according to a Forbes article.
(click to enlarge)
Source: Allied Market Research
The acquisition and the opportunity for ALQA
Alliqua signed a definitive agreement to acquire Eden Prairie-based Celleration for $30.4 million in a cash and stock deal. The cash part of the transaction will be financed by a Senior Secured Term Loan from Perceptive Advisors. The loan amount is $15.5 million. In addition, ALQA will issue 3.2 million shares to fund the remaining roughly $15 million. At the close of the transaction, ALQA would have roughly 19.3 million shares outstanding.
The agreement also includes possibility for additional contingent payments in stock and cash if certain milestones are reached by the end of December 31, 2016. However, at the moment, ALQA is valuing Celleration at 3.5x 2014 sales of $8.7 million, which is in-line with the recent transactions involving public and private wound care companies.
Interestingly, Celleration is developing an ultrasound platform that could be the next generation in wound healing. According to research that has been ongoing for many years, certain kinds of physical waves - PRFE, galvanic currents, ultrasound - can stimulate the underlying cells below a dermal wound to develop their healing properties. Ultrasound wound healing is a disruptive technology that can potentially alter the market dynamics of wound healing, reducing pain and quickening the healing process. So, this technology will nicely complement ALQA's existing range of healing technologies.
In a conference call after the deal was announced, David Johnson, CEO of Alliqua, noted that Celleration has 500 clients in the U.S. and is continuing to place devices actively. In addition, the company has 5 of the 8 MACs, which account for 84% of the market and 44 states, reimbursing for their MIST wound care device, according to Johnson. Further, they sell a disposable to all centers, which includes Mayo Clinic, at a gross margin of 80%. Johnson further noted in the conference call that the device sales are also high margin. Disposables though account for the bulk of Celleration's sales at 80% of the total.
In 2014, Celleration saw its sales slip slightly; however, this was due to capital constraints. In fact, this is the opportunity ALQA has in front of it. If ALQA continues to find targets like Celleration in the wound care market that have innovative and attractively reimbursed products but face capital constraints it can significantly boost its top line. ALQA with its backing from a powerful investor base that includes names such as Celgene has the capacity to fund such small transactions. In fact, CEO Johnson noted that this will be the company's strategy in 2015. He noted the company will focus on three things in 2015 during his conference call. This includes driving adoption of current products with existing salesforce, continuing to look for M&A deals, and continue to seek regional reimbursement for their internal products.
Coming back to the Celleration acquisition and its impact, Johnson said in FY2014, Celleration had revenue per salesperson of $400,000. The average for the devices companies though is around $1 million per salesperson, Johnson noted. Based on this alone, Celleration could achieve organic growth of 150% without even adding any sales personnel.
The acquisition would double ALQA's own salesforce. With the acquisition, Johnson expects ALQA revenue to reach $20 million; however, this is a conservative estimate if the transaction is closed on time. You see ALQA has said that it expects FY2015 revenue to be between $11 million and $13 million. However, this was before the Celleration acquisition as well as before the company received a favorable reimbursement for its products with a Q-code. It may be recalled that this is the same reimbursement that boosted MDXG's sales. MDXG received additional Medicare reimbursement coverage for EpiFix® in December 2013. In 2013, the company's sales totaled $59.18 million. Following the reimbursement in December 2013, the company's sales in the first nine months of 2014 were nearly $79 million.
OSIR also followed a similar trajectory after receiving Medicare reimbursement codes for Grafix in May 2012. In 2011, OSIR's sales totaled $1.26 million. In 2012, sales jumped to $7.85 million and in 2013, the first full year after the receipt of reimbursement, sales climbed to more than $24 million. Based on this trend, I expect ALQA sales to see a positive impact from the Medicare reimbursement. Therefore, I expect sales to be between at least $15 million and $20 million, well above the company's own guidance of $11 million to $13 million. Celleration had sales of $8.7 million. Assuming a 30% growth rate for Celleration sales, this translates to $11 million. So my estimate for ALQA sales this year is around $26 million to $31 million.
Based on this sales estimate and 19.3 million outstanding shares following the close of the Celleration transaction, ALQA shares currently trade at a multiple of 4x. If the stock moves closer to the multiple of MDXG and OSIR, which is around 10x sales, this would give ALQA price per share of $15. Currently, ALQA is not valued like its peers because the company is significantly smaller than its rivals. However, with the acquisition of Celleration, the receipt of favorable reimbursement for its products with a Q-code and possible future accretive acquisitions, ALQA's sales will close the gap between itself and its rivals in terms of sales. This means that its multiple should also move in-line with those for MDXG and OSIR. In fact, given ALQA's strategy of focusing on inorganic growth, a slightly higher multiple would be also justified.
ALQA Could Be An Acquisition Target Itself
Indeed, if you look at Johnson's background this could be a possibility. ALQA's valuation also makes it very attractive right now. Johnson came to ALQA about two years ago from ConvaTec, a leading wound care company. Johnson took ConvaTec to around $1.7 billion in revenue and in 2008 sold it for $4 billion. Interestingly, the sales growth at ConvaTec was driven to a large extent by acquisitions, and this was in just a few years. I would not be surprised if Johnson follows a similar strategy at ALQA. While private companies fetch a lower multiple, for ALQA, I expect a multiple of at least 8x sales if it is ever taken out.
Risk
ALQA had $19.89 million in cash on its balance sheet at the end of September 30, 2014, which given the current burn rate of around $4 million per quarter will last at least until the end of this year. However, if the company will continue to focus on acquisitions, it will have to raise more money or issue more shares (if it is using stock for takeover). In either case, there is a dilution risk. Having said that if the acquisitions are like Celleration i.e. significantly accretive to top and bottom line, the dilution risk will be more than offset.
Another risk is integrating acquired companies. But these are small acquisitions and Johnson has experience in the area, given the success he had at ConvaTec implementing a similar strategy of focusing on inorganic growth.
To sum up, ALQA offers an excellent opportunity for significant upside in the medium term, while the downside risk looks to be minimal.
Alliqua Biomedical: An Attractive Opportunity In The Wound Care Space
Feb. 9, 2015 11:19 AM ET
Alliqua Biomedical this week announced the acquisition of privately held Celleration.
Alliqua’s offer values Celleration at 3.5x sales, which is in-line with the valuation of other privately held companies acquired in recent years.
Listed companies in the wound care space though trade at 10x sales.
Alliqua’s multiple based on FY2015 sales estimate is just 4x.
As Alliqua grows in size through accretive acquisitions like Celleration, its multiple will move in-line with the average.
Alliqua Biomedical (NASDAQ:ALQA) is a Langhorne, Pennsylvania-based company providing advanced wound care solutions. This week, ALQA was in the news after announcing that it will acquire Celleration Inc., a Minnesota-based privately held medical device company providing advanced wound care products.
The acquisition is part of ALQA's strategy to boost its top line. At the same time, the company is looking to take advantage of the opportunity that is currently on offer in the wound care space, which includes public and private companies.
So what is the opportunity here? Acquisitions in the wound care space in recent years have shown that privately held companies can fetch between 2-4x sales. However, listed companies like MiMedx (NASDAQ:MDXG) and Osiris Therapeutics Inc. (NASDAQ:OSIR) are valued at around 10x sales. ALQA itself is valued at 27x sales. However, the company's sales this year will be significantly boosted by the acquisition of Celleration. Based on the FY2015 sales estimate of roughly $30 million and 20 million shares outstanding, ALQA is valued at just 4x sales, which is well below the average for other players in the wound care treatment market. By continuing to acquire privately held wound care companies at a multiple of between 2x and 4x sales, ALQA could significantly boost its revenue. And as the company grows in size, its multiple should also move in-line with those of its bigger rivals. This means that the stock could generate significant returns in the medium term.
Recent Transactions that highlight the discount
In the last few years, the $21 billion wound care market has seen a number of acquisitions. The interesting thing about these acquisitions is that they have involved a public and a private company.
In December 2010, MDXG acquired Surgical Biologics for $7.25 million. In FY2010, Surgical Biologics had $2.2 million in sales, which means that MDXG's offer valued Surgical Biologics at 3.3x sales. Interestingly, MDXG expected the acquisition to accrete over $7 million to the top line in 2011.
In 2012, Derma Sciences (NASDAQ:DSCI) acquired MedEfficiency for $14.5 million. DSCI's offer valued MedEfficiency at 2.7x sales.
Last year in May, Alliqua itself acquired Choice Therapeutics for $4 million in a cash and stock deal. The transaction valued Choice Therapeutics at 2.2x sales. The latest acquisition from ALQA this week continues the trend seen in the wound care market in terms of valuation. ALQA has offered to acquire Celleration for an initial purchase price of approximately $30.4 million in cash and stock. Celleration's sales during the fiscal year ended December 31, 2014, were approximately $8.7 million, which translates to a valuation of roughly 3.5x sales.
Brief on the regenerative wound care market
The Wound Care products market has three major divisions: Traditional (sutures, bandages, tape, etc.), Advanced (antimicrobial, alginate, foam, hydrogel, hydrocolloid dressings) and Regenerative (bioengineered skin, skin substitutes). The total wound care market is worth about $21 billion in 2015, and is projected to grow to $67.5 billion in 2020. "Four major companies, including Smith & Nephew (NYSE:SNN), Kinetic Concepts (KC), Molnlycke, and ConvaTec comprise more than 55% of the $5 billion advanced wound care market, according to Justin Smith, analyst at Societe Generale," which is according to a Forbes article.
(click to enlarge)
Source: Allied Market Research
The acquisition and the opportunity for ALQA
Alliqua signed a definitive agreement to acquire Eden Prairie-based Celleration for $30.4 million in a cash and stock deal. The cash part of the transaction will be financed by a Senior Secured Term Loan from Perceptive Advisors. The loan amount is $15.5 million. In addition, ALQA will issue 3.2 million shares to fund the remaining roughly $15 million. At the close of the transaction, ALQA would have roughly 19.3 million shares outstanding.
The agreement also includes possibility for additional contingent payments in stock and cash if certain milestones are reached by the end of December 31, 2016. However, at the moment, ALQA is valuing Celleration at 3.5x 2014 sales of $8.7 million, which is in-line with the recent transactions involving public and private wound care companies.
Interestingly, Celleration is developing an ultrasound platform that could be the next generation in wound healing. According to research that has been ongoing for many years, certain kinds of physical waves - PRFE, galvanic currents, ultrasound - can stimulate the underlying cells below a dermal wound to develop their healing properties. Ultrasound wound healing is a disruptive technology that can potentially alter the market dynamics of wound healing, reducing pain and quickening the healing process. So, this technology will nicely complement ALQA's existing range of healing technologies.
In a conference call after the deal was announced, David Johnson, CEO of Alliqua, noted that Celleration has 500 clients in the U.S. and is continuing to place devices actively. In addition, the company has 5 of the 8 MACs, which account for 84% of the market and 44 states, reimbursing for their MIST wound care device, according to Johnson. Further, they sell a disposable to all centers, which includes Mayo Clinic, at a gross margin of 80%. Johnson further noted in the conference call that the device sales are also high margin. Disposables though account for the bulk of Celleration's sales at 80% of the total.
In 2014, Celleration saw its sales slip slightly; however, this was due to capital constraints. In fact, this is the opportunity ALQA has in front of it. If ALQA continues to find targets like Celleration in the wound care market that have innovative and attractively reimbursed products but face capital constraints it can significantly boost its top line. ALQA with its backing from a powerful investor base that includes names such as Celgene has the capacity to fund such small transactions. In fact, CEO Johnson noted that this will be the company's strategy in 2015. He noted the company will focus on three things in 2015 during his conference call. This includes driving adoption of current products with existing salesforce, continuing to look for M&A deals, and continue to seek regional reimbursement for their internal products.
Coming back to the Celleration acquisition and its impact, Johnson said in FY2014, Celleration had revenue per salesperson of $400,000. The average for the devices companies though is around $1 million per salesperson, Johnson noted. Based on this alone, Celleration could achieve organic growth of 150% without even adding any sales personnel.
The acquisition would double ALQA's own salesforce. With the acquisition, Johnson expects ALQA revenue to reach $20 million; however, this is a conservative estimate if the transaction is closed on time. You see ALQA has said that it expects FY2015 revenue to be between $11 million and $13 million. However, this was before the Celleration acquisition as well as before the company received a favorable reimbursement for its products with a Q-code. It may be recalled that this is the same reimbursement that boosted MDXG's sales. MDXG received additional Medicare reimbursement coverage for EpiFix® in December 2013. In 2013, the company's sales totaled $59.18 million. Following the reimbursement in December 2013, the company's sales in the first nine months of 2014 were nearly $79 million.
OSIR also followed a similar trajectory after receiving Medicare reimbursement codes for Grafix in May 2012. In 2011, OSIR's sales totaled $1.26 million. In 2012, sales jumped to $7.85 million and in 2013, the first full year after the receipt of reimbursement, sales climbed to more than $24 million. Based on this trend, I expect ALQA sales to see a positive impact from the Medicare reimbursement. Therefore, I expect sales to be between at least $15 million and $20 million, well above the company's own guidance of $11 million to $13 million. Celleration had sales of $8.7 million. Assuming a 30% growth rate for Celleration sales, this translates to $11 million. So my estimate for ALQA sales this year is around $26 million to $31 million.
Based on this sales estimate and 19.3 million outstanding shares following the close of the Celleration transaction, ALQA shares currently trade at a multiple of 4x. If the stock moves closer to the multiple of MDXG and OSIR, which is around 10x sales, this would give ALQA price per share of $15. Currently, ALQA is not valued like its peers because the company is significantly smaller than its rivals. However, with the acquisition of Celleration, the receipt of favorable reimbursement for its products with a Q-code and possible future accretive acquisitions, ALQA's sales will close the gap between itself and its rivals in terms of sales. This means that its multiple should also move in-line with those for MDXG and OSIR. In fact, given ALQA's strategy of focusing on inorganic growth, a slightly higher multiple would be also justified.
ALQA Could Be An Acquisition Target Itself
Indeed, if you look at Johnson's background this could be a possibility. ALQA's valuation also makes it very attractive right now. Johnson came to ALQA about two years ago from ConvaTec, a leading wound care company. Johnson took ConvaTec to around $1.7 billion in revenue and in 2008 sold it for $4 billion. Interestingly, the sales growth at ConvaTec was driven to a large extent by acquisitions, and this was in just a few years. I would not be surprised if Johnson follows a similar strategy at ALQA. While private companies fetch a lower multiple, for ALQA, I expect a multiple of at least 8x sales if it is ever taken out.
Risk
ALQA had $19.89 million in cash on its balance sheet at the end of September 30, 2014, which given the current burn rate of around $4 million per quarter will last at least until the end of this year. However, if the company will continue to focus on acquisitions, it will have to raise more money or issue more shares (if it is using stock for takeover). In either case, there is a dilution risk. Having said that if the acquisitions are like Celleration i.e. significantly accretive to top and bottom line, the dilution risk will be more than offset.
Another risk is integrating acquired companies. But these are small acquisitions and Johnson has experience in the area, given the success he had at ConvaTec implementing a similar strategy of focusing on inorganic growth.
To sum up, ALQA offers an excellent opportunity for significant upside in the medium term, while the downside risk looks to be minimal.
CN...Thanks for your response.
Thinking to myself how it would be pretty neat if the NY Giants and Jets are invited to attend. (maybe even Roger Goodell) Since no opiates are in the new CBD product, this might be a good time to solicit Football players to try it out as their pain medication of choice.
CN.. Regarding "THE" launch
Just curious what your thoughts are concerning the launch.
How do you think they will market and advertise? Will they use more than just a PR. Think there will be a billboard in Times Square?(LOL) Will there be an ad in the NY Times? Any free samples?
ALQA moving past couple of days
Wound care business improving and just announced a merger with privately held company increasing their prospects.
Alliqua BioMedical, Inc. to Acquire Celleration, Inc.
Expands Proprietary Product Portfolio and Salesforce in the Advanced Wound Care Market
LANGHORNE, Pa., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced that it has signed a definitive agreement to acquire Celleration, Inc. ("Celleration") for an initial purchase price of approximately $30.4 million, which is comprised of both cash and stock. The merger agreement provides for additional contingent payments in stock and cash, under certain circumstances, if stated revenue thresholds are reached over the next two years ending December 31, 2016 or if certain milestones are satisfied in connection with product sales in the U.K.
Related Links
PDF
Release PDF
Celleration is a privately held medical device company, based in Eden Prairie, Minnesota, which is focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds. Celleration's MIST Therapy System is an FDA 510(k) cleared device that uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed in order to promote the healing process. Celleration generated total revenue of approximately $8.7 million during its fiscal year ended December 31, 2014. Since Celleration's MIST Therapy System was commercialized in 2005, MIST therapy has been performed more than 1.2 million times on over 85,000 patients in the U.S. and the U.K.
Celleration's MIST Therapy System is supported by extensive clinical study data which has been produced in the past several years showing that MIST Therapy positively impacts critical aspects of the wound healing process. Most recently, in a prospective, randomized controlled trial conducted in 22 U.S. outpatient healthcare facilities and published in the January 2015 edition of Ostomy & Wound Management(1), MIST therapy demonstrated a statistically significant improvement in the healing rate over the standard of care treatment for venous leg ulcers. It is with this body of clinical data that the Mist Therapy was given a new reimbursement payment for outpatient services that became effective January 1, 2015, and we believe now more effectively reflects both the clinical efficacy and the economic benefits of the technology.
"Celleration's innovative MIST therapy technology is positioned perfectly within Alliqua's business model," said David Johnson, Chief Executive Officer of Alliqua. "MIST therapy is a differentiated wound care treatment which is supported by a breadth of data that demonstrates its clinical efficacy and strong economic value proposition. Celleration's therapeutic devices, MIST and UltraMIST™, are FDA 510(k) cleared, receive favorable reimbursement and carry a high-margin profile.
"Likewise, Celleration's focus on developing novel approaches for the treatment of wounds aligns exceptionally well with our vision of building a suite of advanced wound care solutions," continued David Johnson. "In addition to the differentiated product offering, we were attracted to Celleration's leadership role in advancing the science and practice of wound healing in working with medical professionals and providers, which, we believe, has helped the Company earn the favorable reimbursement decision in recent months. Further, this transaction will nearly double our sales force and we look forward to incremental improvements in sales force productivity as we begin marketing the combined company's suite of proprietary products. Finally, we are very pleased to welcome Mark Wagner, Celleration's President and CEO, who will be joining our Board of Directors upon the closing of the transaction."
"This transaction presents an exciting opportunity for the two companies and their employees, who will be able to market a broader portfolio of treatments to a combined customer base and a common call point," commented Mark Wagner, Celleration's President and CEO. "With an impressive product portfolio and sales infrastructure, the combined company will be well-positioned to capitalize on the large and rapidly growing market for advanced wound care treatments. Both companies believe strongly in Evidence Based Medicine and delivering products that accelerate healing and minimize retreatment rates which, most importantly, benefits patients, payers and providers."
Cowen and Company, LLC served as the Alliqua's exclusive financial advisor in connection with this transaction.
Financing
Alliqua has entered into a commitment letter for a Senior Secured Term Loan with Perceptive Advisors in the principal amount of $15.5 million in order to finance the initial cash purchase price.
Further details of the acquisition and commitment letter can be found in Alliqua's Form 8-K that will be filed with the SEC.
Terms and Approvals
The transaction is expected to close in the second quarter of 2015 and is subject to customary closing conditions, including Alliqua shareholder approval.
Conference Call
Alliqua will host a conference call for analysts and investors tomorrow Tuesday, February 3, 2015 beginning at 8:00 a.m. ET to discuss the Celleration transaction. Individuals interested in listening to the conference call may dial 888-337-8198 for domestic callers or 719-325-2469 for international callers and provide access code 2955591. A replay of the call will be available for 14 days and can be accessed by dialing 888-203-1112 for domestic callers or 719-457-0820 for international callers.
The conference call will also be available via a webcast on the "Investors Relations" section of the Company's Web site at: http://ir.alliqua.com/.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond® 3D advanced dressing which incorporates the TheraBond® 3D Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
About Celleration, Inc.:
Celleration, Inc. is a privately held medical device company. Celleration develops and markets a proprietary technology that has been proven to accelerate healing in wounds by delivering therapeutic, low frequency ultrasound without direct contact of the delivery device to the wound surface. Celleration's core product, the MIST Therapy System, has been clinically shown to positively impact all critical aspects of the wound healing process providing clinical and economic benefits to institutions treating nonresponding wounds. MIST therapy has been performed more than 1.2 million times on over 85,000 patients. There are 16 peer reviewed published articles, including five Randomized Controlled Trials and one Meta-analysis, documenting the clinical outcomes of MIST.
CN... Thanks
for posting that info. I went to the link you provided and read the whole thing. Your post #9872 from Oct 6, 2014.
What a great opportunity missed!
Who are these people Green Rush Investors. Just a newsletter or do they also make recommendations?
You mention there were 2 other interview prior to that one. Have there been any others since?
Thanks for all you research and help on this board.
NBM
CN.. Regarding the interview
you are mentioning. I vaguely recall, but don't remember the content. Is there a link to either read or listen to?
Perhaps you could post it here and wherever else you can think of. Was there ever a PR about it? Maybe now is a good time for the company to issue a PR with the interview.
TIA
Alliqua BioMedical Announces Group Purchasing Agreement With Premier, Inc.
Date : 01/05/2015 @ 7:30AM
Source : GlobeNewswire Inc.
Today : Monday 5 January 2015
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced that it has signed a group purchasing agreement for regenerative skin grafting products with Premier, Inc. This agreement offers Premier alliance members access to Alliqua BioMedical's regenerative skin graft products, including Biovance® Human Amniotic Membrane Allograft, at specially negotiated pricing and terms.
Premier is a healthcare improvement company uniting an alliance of approximately 3,400 U.S. hospitals and 110,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.
"This award from Premier to Alliqua BioMedical in the category of Regenerative Skin Grafts is a milestone in the growth story of our company," said Brad Barton, Chief Operating Officer of Alliqua BioMedical. "As we strive to deliver a technological suite of solutions that allow wound care practitioners to manage acute and chronic wounds, our agreement with Premier will allow us to further extend our reach to hospitals and post-acute providers of care. Premier and Alliqua BioMedical are aligned with a focus on healthcare performance improvement - helping providers to realize clinical, financial and operational gains, so that they can sustainably serve the needs of their communities."
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
CONTACT: Investor Relations:
Westwicke Partners on behalf of Alliqua Biomedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
goldmansack
I hear everything you are saying and I am a big believer in NRTI. I just felt a little upset that the relationship was not mentioned and I got the impression they were doing their own thing.
The full text is below and clearly says their partnership is with IVXX and their product was developed by Cannabis Veterans Salwa Ibrahim and Derek Peterson. It says IVXX will be launching a line of expertly produced flowers and joints, as well as a complete line of pure concentrates including; oils, waxes, shatters and clears, produced at the companies flagship extraction lab.
While I hope you are right, I am concerned. Not bashing, as I own quite a bit. (both as a matter of fact)
Terra Tech Introduces IVXX(tm) - A New Brand of Premium Quality, Locally-Produced Cannabis
6:07a ET December 10, 2014 (GlobeNewswire) Print
Terra Tech Corp (TRTC) is pleased to announce a new brand of exceptional quality cannabis products. IVXX, a wholly-owned subsidiary of Terra Tech, was developed by cannabis veterans Salwa Ibrahim and Derek Peterson, who believe in cannabis and its associated benefits. They and their entire IVXX team are committed to building a brand that delivers benchmark quality and consistency.
"We believe everyone deserves the finest cannabis products and experiences. Our goal in developing this brand is to make certain we bring much-needed quality and accountability to the entire industry. The industry is maturing to a point where thoughtful branding is needed so consumers can make educated and informed decisions about the products they purchase." - Derek Peterson, CEO, Terra Tech
By partnering closely with their carefully selected team of experienced and trusted cultivators, they can ensure their cannabis is grown and harvested under the safest and most beneficial conditions. Their products, including flowers, pre-rolled joints and concentrates, are thoughtfully produced, rigorously tested and certified to the highest standards of potency and purity. All IVXX products are free of toxic pesticides, harmful molds and chemical residues.
"We are very fortunate to work with leaders in the cannabis cultivation industry who take tremendous pride and care in producing their crops. Our partners share our dedication in producing the highest quality cannabis, so our consumers can be assured they're getting the best products available." - Salwa Ibrahim, CEO, IVXX
The IVXX team is committed to becoming the industry's most trusted purveyor of high quality cannabis. They intend to grow the brand slowly and mindfully, thereby guaranteeing they deliver only the best products possible to their consumers.
IVXX will be launching a line of expertly produced flowers and joints, as well as a complete line of pure concentrates including; oils, waxes, shatters and clears, produced at the companies flagship extraction lab. All of these products will be available at select retailers throughout Northern California, Nevada and other states. The IVXX branded products will be produced, packaged and distributed in full compliance with state regulations. The IVXX Sampler Kit is featured in the High Times Magazine Holiday Gift Guide. IVXX will launch their full website in the coming weeks. The site will have in-depth information about the products, processes and retail availability.
For more information about IVXX, please visit: www.ivxx.com.
Follow us on IVXX on Facebook, Twitter and Instagram.
For more information about Terra Tech Corp, please visit: www.terratechcorp.com
Visit us on Facebook @ http://www.facebook.com/terratechcorp
Follow us on Twitter @terratechcorp
I can't wait to see the PR explaining more about what is taking place.
golmansack. TRTC/NRTI
I was a little confused by TRTC PR today. I did not see NRTI mentioned at all and got the impression that they were doing their own thing and had their own experts.
At least they were transparent in their efforts and gave a possible schedule of events, something CN espoused a few days ago for us.
Hope I am wrong about TRTC plans, but could someone please show me where?
Karen... Thanks
Want to thank you for calling this one to my attention.
Thanks for all your SA articles.
You were early but 100% spot on.
Thanks!
Four Officers purchased shares on open MKT
Pascoe 12,000
Smith 26,500
Ray 3,500
Wierenga 20,000
Shows pretty good confidence.
go APRI
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, and image processing software and workstations for use in medical, scientific, and industrial settings, as well as for security and non-destructive testing. Varian Medical Systems employs approximately 6,800 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.
Benzinger reporting buyout deal!
Benzinger reporting:Hearing Deal Reporter Says Varian Medical Interested in IsoRay
10/24/2014 09:42 AM Came over TDA News for ISR
CN.... Is the company eligible for any more funds from the
New Jersey Technology Business Tax Certificate Transfer Program?
If so, do you know how much?
TIA
Hope you are right.
How long will it take before we hear that it is approved or rejected?
Anyone know why trading was halted today?
New Financing!! Bah!!!
Unless I am missing something this new deal leaves a lot to be desired.. From the press release:
Apricus Biosciences (NASDAQ:APRI) enters into a common stock purchase agreement with Aspire Capital Fund LLC. Aspire purchased 1,159,824 shares for $2.0M when the contract was signed and has committed to purchase up to $20.0M of additional stock over the next 24 months based on market prices.
Apricus will issue 255,161 shares of common stock to Aspire as a commitment fee pursuant to the consummation of the agreement.
So that means the initial 1.1 million shares have an average purchase price of $1.72 when adding in the commitment fee of 255,161 "FREE" shares that brings the share price down to only $1.41.
Are we to see them selling these shares into the market and surpressing share price?
I may be completely off base....And then I think I saw something about a $100 million shelf registration. Boy,I think we are in trouble..
Please tell me we are going to be ok..
Travelers 79
Thanks for your response.. Sounds good to me along with todays news release.
GLTA...
Traveler 79...$10 a share!!
I hope you are right, but what are you basing this on?
eicoman...
If Rayva goes thru US clinical trials and gets approved for Raynauds or RA, or whatever, is there anything from keeping physicians from writing off label prescriptions for ED?
Certainly would be a way to get around Vitaros ownership in US!!!
I know its a few years away, but by then there should be all types of success stories from all over Europe..
Eicoman,
Great to hear they will be in Boston.
Maybe the CC will have good news in advance of that.
WE can sure hope (and PRAY).
Would like to see some PR about this presentation and potential schedule.
Maybe they are in Boston
to present the next day at the Cannacord Genuity Conference at the Intercontinental in Boston Aug 13-14..
One can wish!
And then maybe they present at Rodman and Renshaw in Sept. in NYC
bcpark
Any exposure is better than NONE!
Cardinal Health is well none and respected..
NRTI to present MSE at Cardinal Health
Inergetics to Present Martha Stewart™ Essentials at Cardinal Health's Retail Business Conference in Washington, D.C.
Today : Wednesday 23 July 2014
NEWARK, N.J., July 23, 2014 /PRNewswire/ -- Inergetics, Inc. (OTCBB: NRTI), a leading developer of nutritional supplements, is proud to announce that the company will be presenting Martha Stewart™ Essentials, its line of whole-food-based vitamin supplements developed in concert with Martha Stewart herself at Cardinal Health's Retail Business Conference (RBC), the independent pharmacy industry's top tradeshow. RBC will be held at the Gaylord National Resort & Convention Center in Washington, D.C. July 23 through July 26.
Martha Stewart Essentials supplements were developed by Martha Stewart in consultation with nutritional science experts to support the overall health and wellness of women. They contain the finest, natural whole-food ingredients including fruits, vegetables and herbs. Guided by her concept of whole, healthy living at every age, the supplements focus on specific needs affecting women, including a multi-vitamin; graceful aging; digestive health; bone support; menopause support; hair, skin & nails as well as the all new vegetarian multi-vitamin gummies.
RBC will welcome more than 7,000 participants from across the industry this year. The host of the event, Cardinal Health, is a Fortune 500 company that specializes in distribution of health and medical products serving more than 60,000 locations. Visitors can stop by the Inergetics table, where the entire line of Martha Stewart Essentials will be presented, and Martha Stewart autographed copies of her New York Times bestselling book "Living the Good Long Life" will be raffled off.
"We are thrilled to have the opportunity to showcase the Martha Stewart Essentials product line at such a prominent event," said Scott Zitiello, National Sales Director of Inergetics. "We're looking forward to partnering with Cardinal Health to reach even more women, helping them to lead the vibrant, healthy lifestyle our line of products promotes."
"At Inergetics, we are committed to providing our customers with innovative, high-quality nutritional supplements that support their healthy, active lives," said Mike James, CEO of Inergetics. "We are excited to expand our distribution to the large number of stores Cardinal Health provides.
Launched in 1990, RBC is an annual pharmacy conference hosted by Cardinal Health to celebrate the history and value of independent pharmacy and to provide opportunities for independent pharmacy owners to learn how to expand and thrive in the business. More information about this year's event as well as its sponsors and exhibitors, can be found at http://rbc.cardinalhealth.com/CardinalHealth/RBC/2014/Home.
Media Contact
RLM Finsbury
(646) 805-2025
Inergetics@rlmfinsbury.com
About Inergetics, Inc.
Inergetics' portfolio of brands includes: Martha Stewart™ Essentials, a complete line of whole-food-based supplements created specifically for women; Surgex® Sports Nutrition, the preferred nutritional supplement of Army Sports; Bikini Ready®, a leader in weight loss lifestyle solutions; SlimTrim, the affordable, premium value diet brand; and OmEssentials®, a line of scientifically advanced nutritional supplements designed to further the health and wellness of yoga practitioners and active individuals.
To learn more about Inergetics, visit www.inergetics.com, and the Inergetics brand websites: www.marthastewartessentials.com, www.surgexsports.com, www.surgexsportsblitz.com, www.slimtrim1.com, www.slimtrim.net, www.bikinireadylifestyle.com, www.kahunasands.com, www.omessentials.com.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of Inergetics set forth herein and those preceded by or that include the words "believes," "expects," "given," "targets," "intends," "anticipates," "plans," "projects," "forecasts," or similar expressions, are "forward-looking statements." Although Inergetics' management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause Inergetics' future results to differ materially from those anticipated. Inergetics assumes no obligation to update any of the information contained or referenced in this press release.
SOURCE Inergetics, Inc.
Rodman & Renshaw 9/8-10
Rodman and Renshaw 16th Annual Global Investment Conference to be held in New York at the NY Palace Hotel on Sept 8 thru 10.
IMO, This would be a perfect opportunity to share with the investing community progress of Vitaros and Femprox.
http://www.meetmax.com//sched/event_23003/~public/conference_home.html?event_id=23003